You are here

Non-invasive Tracking of iPSC-Cardiomyocytes

In vivo imaging techniques can help to guide the clinical translation of cell‐based therapeutics; however, immunogenicity and potential genotoxicity currently limited related strategies. In a proof‐of‐principle study published in STEM CELLS Translational Medicine, researchers led by Cynthia E. Dunbar and So Gun Hong (National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA) report how the site‐specific delivery of the sodium/iodide symporter (NIS) gene via CRISPR/Cas9 gene-editing technology enabled the sensitive in vivo tracking of induced pluripotent stem cell‐derived cardiomyocytes (iPSC‐CM) in a clinically relevant model of myocardial infarction. Furthermore, Ostrominski and Yada et al. established that NIS‐positive iPSC‐CMs retained electrophysiological characteristics when compared to controls. Featuring a superior safety profile, this approach offers broader applications in both the preclinical and clinical development of cardiac cell therapies.